人参愈伤组织源性细胞系表达人胰岛素的研究
|
摘要
目前,生产人胰岛素大多采用人工合成、化学提取和基因工程等方法。基因工程生产人胰岛素一般用大肠杆菌表达,且表达的胰岛素是以胰岛素原的形式存在。它必需经过后序处理,才具有生物活性。而且它的使用大多以注射为主,既麻烦又给病人带来一定的痛苦。
随着生物技术的发展,对天然药物研究的开发和利用越来越得到人们的重视。本研究首次将构建了霍乱毒素B亚单位(CTB)与人胰岛素融合蛋白基因的植物表达载体通过农杆菌感染而将其整合到了人参愈伤组织细胞的染色体上,结果表明人胰岛素基因在人参愈伤组织细胞内得以表达。从小鼠实验看出,人参细胞亦有降血糖作用,而转化了人胰岛素基因的人参细胞的降血糖作用更明显,与非转化的人参细胞相比具有显著性差异。但小鼠的甘油三酯和胆固醇下降不明显。
本研究设计独特,充分发挥了霍乱毒素B亚单位(CTB)的肠道吸附作用与人胰岛素的治疗作用,并将它们通过人参细胞表达,使得现代生物技术与我国的传统中药有机地结合在一起,为今后胰岛素的口服用药开辟了一条新路。
Diabetes is a kind of chronic disease ,the statistic data indicates that the quantities of diabetes suffers have the increasing tendency year by year ,and now injecting insulin is the most effective method for prevention of diabetes. At present , the production of insulin mostly use the methods of synthesis , chemical extraction and genetic engineering and so on , and insulin is usually expressed by Eco.li . But the expression product is pre-insulin , which has no activity , it only can be used after being handled . In the same time, injection brings the pain to the patients . This research goal lies in that we can construct CTB-human insulin fusion gene plant expression vector,and introduce fusion gene into cell chromosome in ginseng cell line through
Agrobacterium–mediated transformation system ,so that we can establish ginseng cell lines expressing CTB-human insulin fusion proteins for oral medication in future .
First ,we select ginseng cell biased codons according to the cDNA sequence of human pre-insulin signal peptide (SP) ,chain B ,chain A , chain C and CTB gene provided by Gene Bank , transform human pre-insulin (SPBCA) and CTB separately ,and design Furin proteinase digestion position spots on two ends of chain C and three GP peptides on C end of chain C . SPBCA gene and CTB gene are amplied by PCR method ,after that BCA gene and BA gene are also amplied with the template SPBCA . Four fragments of purpose genes are sub-coloed into the vectors pMD18-T to construct the vectors pMSPBCA , pMBCA ,pMBA, pMCTB. The colone vectors are digested by corresponding enzyme ,and the goal gene fragments SPBCA ,BCA ,BA and vector fragment pMD-CTB are recycled , then they are constructed into fusion clone vectors pMCSPBCA , pMCBCA , pMCBA . In the same , these fusion clone vectors are digested by BamH I and Sac I , the fusion gene fragments CTB-SPBCA , CTB-BCA , CTB-BA are recycled , and then they are separtely cloned to real nuclear expression vector pBI121 to become plant expression vectors pBCSPBCA , pBCBCA , pBCBA . Recombinant plasmids are extracted to be transformed into Agrobacterium LBA4404 , the fusion genes are separtely transinfected and joined into ginseng cell line through Agrobacterium–mediated transformation method . Their cell genome DNA is extracted after screening positive cell strains with 67-V medium including 50mg/L of G418 , then the fusion genes are detected if they have been introduced into the chromosome of ginseng cells by PCR method . In the same , their cell total mRNA is also extracted to prove their existence of duplication products for fusion genes through RT-PCR method and agarose gel electrophoresis . Western-blotting method and ELISA method are used to detect goal fusion proteins and their protein contents .In addition to , non-transformed ginseng cells , transformed ginseng cells and sterile physiological saline are respectively injected into mouse abdominal cavity and administrated orally to examine the changes of blood sugar ,the triglyceride and the total cholesterol density after injection , as well as blood sugar density change after oral administration .
The experimental results show that CTB-SPBCA , CTB-BCA , CTB-BA fusion genes have successfully been introduced into the ginseng cells , it has been identified by enzyme digestion reaction of PCR products with screened transgenic cell genome DNA as the template . Total mRNA of transgenic cell is extracted , it has been proved by RT-PCR reaction and the agarose gel electrophoresis that duplication products of CTB-SPBCA , CTB-BCA , CTB-BA genes are existent . Western-blotting examination result shows that the special protein bands appear at these positions whose relative molecular weight are 25KD , 23KD and 19KD , this demonstrates that three kinds of fusion proteins can specially combine with human insulin antibody . ELISA method test shows that goal proteins have been expressed , Protein contents of CTB-SPBCA , CTB-BCA , CTB-BA are respectively 6.03uIU/ml , 6.81uIU/ml , 5.31uIU/ml . The mouse blood sugar examination results indicate that ginseng cell can decrease the content of blood sugar , transformed ginseng cell is more remarkable in falling the content of blood sugar , but the contents of triglyceride and the total cholesterol change little . non-transformed ginseng cell supernate , transformed ginseng cell supernate and steril physiological saline are respectively injected into mouse abdominal cavity and administrated orally to examine the changes of blood sugar ,the triglyceride and the total cholesterol density around injection , as well as blood sugar density change around oral administration . After the results are handled by SPSS13.0 statistics software ,the repetition survey variance analysis finds that three group blood sugar values after injection have obvious difference with the values before injection (the P values are 0.000) . The values of blood sugar all decrease in non-transformed ginseng cell group and transformed ginseng cell group ,but its value of blood sugar is high in blank control group . The value of blank control group has obvious difference with that of non-transformed ginseng cell group and transformed ginseng cell group( the P value are 0.000) , and it is the same for non-transformed ginseng cell group and transformed ginseng cell group(the P value is 0.019) , transformed ginseng cell group is more remarakable in the function of falling blood sugar .But the contents of triglyceride and total cholesterol between transformed group and non-transformed group have no significant difference . The values of blood sugar all decrease in non-transformed ginseng cell group and transformed ginseng cell group on 2 hours and 6 hours after oral administration compared with pre-administration, the difference is remarkable (P<0.05) , but its value of blood sugar changes a little in blank control group , there is not notable difference between pre-administration and post-administration . transformed ginseng cell group is obviously different from non-transformed ginseng cell group , transformed ginseng cell group is more remarakable in the function of falling blood sugar . The diference of blood sugar values are not remarkable on 24 hours after oral administration .
In a word , this study has successfully constructed plant expression vectors pBCSPBCA , pBCBCA and pBCBA containning CTB-insulin fusion genes , and obstained transgenic ginseng cell line that can express CTB-insulin fusion proteins through transformation method mediated by Agrobacterium , it has also been proved by animal test . These have laid a good foundation for the development and application of oral administration insulin preparation , and also opened a new road for the development of natural medicine .
随着生物技术的发展,对天然药物研究的开发和利用越来越得到人们的重视。本研究首次将构建了霍乱毒素B亚单位(CTB)与人胰岛素融合蛋白基因的植物表达载体通过农杆菌感染而将其整合到了人参愈伤组织细胞的染色体上,结果表明人胰岛素基因在人参愈伤组织细胞内得以表达。从小鼠实验看出,人参细胞亦有降血糖作用,而转化了人胰岛素基因的人参细胞的降血糖作用更明显,与非转化的人参细胞相比具有显著性差异。但小鼠的甘油三酯和胆固醇下降不明显。
本研究设计独特,充分发挥了霍乱毒素B亚单位(CTB)的肠道吸附作用与人胰岛素的治疗作用,并将它们通过人参细胞表达,使得现代生物技术与我国的传统中药有机地结合在一起,为今后胰岛素的口服用药开辟了一条新路。
Diabetes is a kind of chronic disease ,the statistic data indicates that the quantities of diabetes suffers have the increasing tendency year by year ,and now injecting insulin is the most effective method for prevention of diabetes. At present , the production of insulin mostly use the methods of synthesis , chemical extraction and genetic engineering and so on , and insulin is usually expressed by Eco.li . But the expression product is pre-insulin , which has no activity , it only can be used after being handled . In the same time, injection brings the pain to the patients . This research goal lies in that we can construct CTB-human insulin fusion gene plant expression vector,and introduce fusion gene into cell chromosome in ginseng cell line through
Agrobacterium–mediated transformation system ,so that we can establish ginseng cell lines expressing CTB-human insulin fusion proteins for oral medication in future .
First ,we select ginseng cell biased codons according to the cDNA sequence of human pre-insulin signal peptide (SP) ,chain B ,chain A , chain C and CTB gene provided by Gene Bank , transform human pre-insulin (SPBCA) and CTB separately ,and design Furin proteinase digestion position spots on two ends of chain C and three GP peptides on C end of chain C . SPBCA gene and CTB gene are amplied by PCR method ,after that BCA gene and BA gene are also amplied with the template SPBCA . Four fragments of purpose genes are sub-coloed into the vectors pMD18-T to construct the vectors pMSPBCA , pMBCA ,pMBA, pMCTB. The colone vectors are digested by corresponding enzyme ,and the goal gene fragments SPBCA ,BCA ,BA and vector fragment pMD-CTB are recycled , then they are constructed into fusion clone vectors pMCSPBCA , pMCBCA , pMCBA . In the same , these fusion clone vectors are digested by BamH I and Sac I , the fusion gene fragments CTB-SPBCA , CTB-BCA , CTB-BA are recycled , and then they are separtely cloned to real nuclear expression vector pBI121 to become plant expression vectors pBCSPBCA , pBCBCA , pBCBA . Recombinant plasmids are extracted to be transformed into Agrobacterium LBA4404 , the fusion genes are separtely transinfected and joined into ginseng cell line through Agrobacterium–mediated transformation method . Their cell genome DNA is extracted after screening positive cell strains with 67-V medium including 50mg/L of G418 , then the fusion genes are detected if they have been introduced into the chromosome of ginseng cells by PCR method . In the same , their cell total mRNA is also extracted to prove their existence of duplication products for fusion genes through RT-PCR method and agarose gel electrophoresis . Western-blotting method and ELISA method are used to detect goal fusion proteins and their protein contents .In addition to , non-transformed ginseng cells , transformed ginseng cells and sterile physiological saline are respectively injected into mouse abdominal cavity and administrated orally to examine the changes of blood sugar ,the triglyceride and the total cholesterol density after injection , as well as blood sugar density change after oral administration .
The experimental results show that CTB-SPBCA , CTB-BCA , CTB-BA fusion genes have successfully been introduced into the ginseng cells , it has been identified by enzyme digestion reaction of PCR products with screened transgenic cell genome DNA as the template . Total mRNA of transgenic cell is extracted , it has been proved by RT-PCR reaction and the agarose gel electrophoresis that duplication products of CTB-SPBCA , CTB-BCA , CTB-BA genes are existent . Western-blotting examination result shows that the special protein bands appear at these positions whose relative molecular weight are 25KD , 23KD and 19KD , this demonstrates that three kinds of fusion proteins can specially combine with human insulin antibody . ELISA method test shows that goal proteins have been expressed , Protein contents of CTB-SPBCA , CTB-BCA , CTB-BA are respectively 6.03uIU/ml , 6.81uIU/ml , 5.31uIU/ml . The mouse blood sugar examination results indicate that ginseng cell can decrease the content of blood sugar , transformed ginseng cell is more remarkable in falling the content of blood sugar , but the contents of triglyceride and the total cholesterol change little . non-transformed ginseng cell supernate , transformed ginseng cell supernate and steril physiological saline are respectively injected into mouse abdominal cavity and administrated orally to examine the changes of blood sugar ,the triglyceride and the total cholesterol density around injection , as well as blood sugar density change around oral administration . After the results are handled by SPSS13.0 statistics software ,the repetition survey variance analysis finds that three group blood sugar values after injection have obvious difference with the values before injection (the P values are 0.000) . The values of blood sugar all decrease in non-transformed ginseng cell group and transformed ginseng cell group ,but its value of blood sugar is high in blank control group . The value of blank control group has obvious difference with that of non-transformed ginseng cell group and transformed ginseng cell group( the P value are 0.000) , and it is the same for non-transformed ginseng cell group and transformed ginseng cell group(the P value is 0.019) , transformed ginseng cell group is more remarakable in the function of falling blood sugar .But the contents of triglyceride and total cholesterol between transformed group and non-transformed group have no significant difference . The values of blood sugar all decrease in non-transformed ginseng cell group and transformed ginseng cell group on 2 hours and 6 hours after oral administration compared with pre-administration, the difference is remarkable (P<0.05) , but its value of blood sugar changes a little in blank control group , there is not notable difference between pre-administration and post-administration . transformed ginseng cell group is obviously different from non-transformed ginseng cell group , transformed ginseng cell group is more remarakable in the function of falling blood sugar . The diference of blood sugar values are not remarkable on 24 hours after oral administration .
In a word , this study has successfully constructed plant expression vectors pBCSPBCA , pBCBCA and pBCBA containning CTB-insulin fusion genes , and obstained transgenic ginseng cell line that can express CTB-insulin fusion proteins through transformation method mediated by Agrobacterium , it has also been proved by animal test . These have laid a good foundation for the development and application of oral administration insulin preparation , and also opened a new road for the development of natural medicine .
引文
1. Damien Bresson and Matthias von Herrath . Mechanisms underlying type 1 diabetes . Drug Discovery Today : Disease Mechanisms , Volume 1, Issue 3, December 2004 , Pages 321-327.
2. Brandy Panunti, Ali . Jawa and Vivian A. Fonseca . Mechanisms and therapeutic targets in type 2 diabetes mellitus .Drug Discovery Today: Disease Mechanisms , Volume 1, Issue 2, November 2004, Pages 151-157
3. Cécile Dantzer, JoelSwendsen, Sylvie Maurice-Tison and ect . Anxiety and depression in juvenile diabetes : A critical review . Clinical Psychology Review , Volume 23,Issue 6, November 2003, Pages 787-800)
4. (Shaila Rodrigues, Elizabeth J Robinson, Heberto Ghezzo and ect . Interaction of body weight and ethnicity on risk of gestational diabetes mellitus . American Journal of Clinical Nutrition, Vol . 70, No. 6, 1083-1089, December 1999 )
5. Kathryn E. Wellen and G?khan S. Hotamisligil . Inflammation, stress, and diabetes . J. Clin. Invest. 115:1111-1119(2005))
6. D Kelleher and S Islam .The problem of integration: Asian people and diabetes . Journal of the Royal Society of Medicine , Vol 87 , Issue 7 414-417
7. Jaakko Tuomilehto, Gang Hu and Siamak Bidel . Coffee Consumption and Risk of Type 2 Diabetes Mellitus Among Middle-aged Finnish Men and Women . JAMA. 2004; 291:1213-1219.
8. Harold Lebovitz . Diabetes: Assessing the pipeline . Atherosclerosis Supplements , Volume 7,Issue 1, April 2006, Pages 43-49
9. Larissa Avilés-Santa,Karin Salinas, Beverley Adams-Huet and ect . Anthropometric features and cardiovascular risk in young LatinAmericans with type 2 diabetes mellitus . Jounrnal of Diabetes and its Complications . Volume 20, Issue 2, March-april 2006, Pages 69-74
10. Jennifer B.Marks and Philip Raskin . Cardiovascular risk in diabetes A brief review . Journal of Diabetes and its Complications , Volume
14,Issue 2, March-April 2000,Pages 108-115
11. Hashem B. EI-Serag, Howard Hampel and Fariba Javadi. The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic Evidence . Clinical Gastroenterology and Hepatology , Volume 4,Issue 3, March 2006, Pages 369-380
12. Francesco Chiarelli, Knut Dahl-J?rgensen , and Wieland Kiess. Diabetes in Childhood and Adolescence . Pediatric and Adolescent Medicine . Vol. 10
13. Brenda Leese . The costs of diabetes and its complications . Social Science & Medicine , Volume 35,Issue 10, November 1990, Pages 1303-1310
14. John A. Galloway . Current trends in diabetes therapy . Trends in Pharmacological Sciences , Volume 5, 1984, Pages 33-35
15. Dr.Linda Rae Zeitzoff MS, RN, CPNP, CDE. A Comprehensive Teview of Insulin Pump Therapy for the Nurse Practitioner . The Journal for Nurse Practitioners , Volume 1, Issue 4, November-December 2005, Pages 201-206
16. JW Anderson and AO Akan ji. Dietary fiber—an overview . Diabetes Care, Vol 14, Issue 12 1126-1131
17. MD FACP, FACELawrence Blonde, Director . Current challenges in diabetes management . Clinical Cornerstone , Volume 7, supplement 3, 2005, Pages S6-S17 Realizing Near-Normoglycemia
18. A Sharma and R Stein . Glucose-induced transcription of the insulin gene is mediated by factors required for beta-cell-type-specific expression . Mol Cell Biol . 1994 February; 14(2):871-879
19. M S German and J Wang . The insulin gene contains multiple transcriptional elements that respond to glucose . Mol Cell Biol. 1994 June; 14(6):4067-4075)
20. D J Drucker, J Philippe ,S Mojsov and ect . Glucagon-like peptide I Stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line . Proc Natl Acad Sci USA. 1987 May; 84(10): 3434-3438
21. Anders Lindholm MD, PhD, Associate Professor . New insulins in the treatment of diabetes mellitus . Best Practice & Research Clinical Gastroenterology , Volume 16, Issue 3, June 2002, Pages 475-492
22. P.Calceti , S.Salmaso and G.Walker ., et al . Development and in vivo evaluation of an oral insulin-PEG delivery system . European Journal of Pharmaceutical Sciences . 2004; 22(4), Pages 315-323
23. S.Sajeesh and Chandra P.Sharma . Ctclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticlesfor oral insulin delivery . International Journal of Pharmaceutics . online 18 June 2006
24. Mariko Morishita , Takahiro Goto and Koji Nakamura ., et al . Novel oral insulin delivery systems based on complexation polymer hydrogels: Single and multiple administration studies in type 1 and 2 diabetic rats . Journal of Controlled Release . 2006; 110(3), Pages 587-594
25. Eiichi Toorisaka, Masakazu Hashida and Noriho Kamiya ., et al . An enteric-coated dry emulsion formulation for oral insulin delivery . Journal of Controlled Release . 2005; 107(1) , Pages 91-96
26. Na Zhang , Qi N. Peng and H.Huang ., et al . Investigation of lectin-modified insulin liposomes as carriers for oral administration . International Journal of Pharmaceutics . 2005; 294(1-2) , Pages 247-259
27. Hou Zhenqing , Zhang Zhenxi and Zhang Chuanxin ., et al . Use of natural plant exudates (Sanguis Draxonis ) for sustained oral insulin delivery with dramatic reduction of glycemic effects in diabetic rats . Journal of Controlled Release . 2004; 97(3) , Pages 467-475
28. T.Morc?l , P.Nagappan and L.Nerenbaum ., et al . Calcium phosphate-PEG-insulin-casein(CAPIC) particles as oral deliverysystems for insulin . International Journal of Pharmaceutics . 2004; 277(1-2), Pages 91-97
29. Kiefer D, Pantuso T.Am Fam Physician, 2003, 68(8): 1539-1542
30. Li Liyan , Lu Xinguo .The Latest Study Progression of Panaxoside . Journal of Sichuan Continuing Education College of Medical Sciences . 2004;23(4)
31. Wang Yan and Ma Wenqiang . Research advance of the biological functions of ginsenoside . Feed industry. 2006 ; 27(6)
32. Xin Ying , Ni Jinsong , Jiang Xin ., et al. Inhibitory effect of
20(s)-ginsenoside Rg3 on tumor growth . Journal of Jilin University (medicine edition). 2006; 32(1)
33. Zhou Liang , Li Xianghua ,Pi Yihua ., et al. Effects of ginsenoside Rg1 on carbohydrate metabolism during exercise in rats . CHINESE JOURNAL OF CLINICAL REHABILITATION . 2005; 39(9)
34. Wang Ying , Cai Donglian . Advances of Research on Anti - Fatigue Effects of Panax ginseng . AMINO ACIDS AND BIOTIC RESOURCES . 2005; 27(3)
35. Feng Yinglu . Ginsenoside and tumor . FOREIGN MEDICAL SCIENCES (ONCOLOGYR SECTION) . 2005;32(9)
36. Zhang Aimin . Effect of the Ginseng(P. schin-seng Nees.)on the Endurance Capacity of Mice . JOURNAL OF LIAOCHENG TEACHERS UNIVERSITY (NATURAL SCIENCE EDITION) . 2001; 14(3)
37. Zhang Nianzhi , Han Mingxiang ,Zhou Yixuan . Clinical Study on Ginseng Injection for Patients with Deficiency of Heart-Qi Syndrome of Angina . JOURNAL OF EMERGENCY SYNDROMES IN CHINESE MEDICINE . 2000 ; 9(4)
38. Li Liyan , Lu Xinguo . Effect of ginsenoside on cardiovascular and neurological systems and its role against exercise-induced fatigue . CHINESE JOURNAL OF CLINICAL REHABILITATION . 2005; 16(9)
39. Wang Jiyan , Shun Guangzhi , Li Xianggao . A Review of the Studies on Chemical Constituents and Pharmaceutical Activities of the Fruitof Panax ginseng . JOURNAL OF JILIN AGRICULTURAL UNIVERSIT .2005; 27(1)
40. Wang Weixia , Wang Wei ,Chen Keji . Protective Effect and Mechanism of Ginsenosides on Central Nerve System of Animals . CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE . 2005;25(1)
41. Wan Xuying , Zhang Yani , Zhang Chen . Experimental Study on Anti-hepatocarcinoma Effect of Maorenshen injection in vitro . JOURNAL OF ZHEJIANG COLLEGE OF TRADITIONAL CHINESE MEDICINE .2004;28(2)
42. Fu Xiaoqing , Cai Zhongwei, Yang Xianrong. General Situation Study of Ginseng delaying senile process of central nervous system(CNS) . CHINESE ARCHIVES OF TRADITIONAL CHINESE MEDICINE .2003;21(7)
43. Wu Chenglin , Gao Pingyang. Study on Ginseng Increasing Mouse Ability of Sports and Fatigue Strength . SICHUAN SPORTS SCIENCE. 2003;1
44. Dan Hanxiong, Liu Chuixia , Jiang Nan. Immunoenhancement Effects of Panaxadiol Saponins Isolated from Panax Notoginseng on Experimental Animal. JOURNAL OF HUBEI COLLEGE TRADITIONAL CHINESE MEDICINE . 2003;5(1)
45. 任杰红,陈林芳,张路晗等。人参皂苷 Rg1 的免疫促进作用。中药新药与临床药理 。2002;13(2)
46. Yu Lijun,Dou Deqiang,Chen Xiaohong., et al. Ginsenoside-Ro enhances cell proliferation and modulates Th1/Th2 cytokines production in murine splenocytes . ACTA PHARMACEUTICA SINICA .2005; 40(4)
47. Jongsung Lee, Eunsun Jung, Jiyoung Lee., et al . Panax ginseng induces human Type I collagen synthesis through activation of Smad signaling . Journal of Ethnopharmacology . 2006; Avalable online 3 July
48. Zhijun Song , Claus Moser, Hong Wu ., et al . Cytokine modulating effect of ginseng treatment in a mouse model of Pseudomonasaeruginosa lung infection . Journal of Cystic Fibrosis .2003; 2,( 3), Pages 112-119
49. Chi Dakui , Yu Xiaofeng, Qu Shaochun., et al. Effect of 20S-protopanaxadiol saponins on blood lipid metabolism and antioxidative activity in hyperlipidemia rats . CHINESE TRADITIONAL AND HERBAL DRUGS . 2004;35(4)
50. Xu Chengshui , Zhang Xiangpei. The influence of red ginseng (P. schin-seng Nees . ) on blood sugar in rat. JOURNAL OF TAISHAN UNIVERSITY.2003;25(3)
51. Wang Benxiang,Zhou Qiuli,Yang Ming ., et al. Hypoglycemic mechanism of ginseng glycopeptide . ACTA PHARMACOLOGICA SINICA. 2003;24(1)
52. Chen Guanmin, Chen Xiaoping, He Ling ., et al . An Experimental Study on Function of Ginseng in Lipid Level and Anti-aging . PRACTICAL PREVENTIVE MEDICINE. 2002;9(4)
53. Luo Lan , Yin Huijun, Zhang Ying., et al. Effect of ginseng fruit saponins on insulin sensitivity index in high fat-fed rats. JOURNAL OF CHINESE INTEGRATIVE MEDICINE. 2005;6(3)
54. Zhang Xinmu , Qu Shaochun, Chi Dakui ., et al. Effects of ginsenoside-Rb on blood lipid metabolism and anti-oxidation in hyperlipidemia rats. CHINA JOURNAL OF CHINESE MATERIA MEDICA. 2004;29(11)
55. Hideyuki Kajiwara , Andrew M.Hemmings and Hisashi Hirano . Evidence of metal binding activities of pentadecapeptide from Panax ginseng . Journal of Chromatography B: Biomedical Sciences and Applications . 1996; 687( 2 ), Pages 443-448
56. ChunXiang Qiao , Ryousuke Den and Koutaro Kudo ., et al . Ginseng enhances contextual fear conditioning and neurogenesis in rats. Neuroscience Research . 2005; 51(1) , Pages 31-38
57. Jacek Osek ,Michael Lebens and Jan Holmgren . Improved medium for large-scale production of recombinant cholera toxin B subunit for vaccine purposes . Journal of Microbiological Methods . 1995; 24(2), Pages 117-123
58. J.Sanchez ,S.Johansson,B.L?wenadler ,et al . Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination. Research in Microbiology . 1990; 141(7-8) , Pages 971-979
59. Bernard de Geus , Maike Dol-Bosman , Jan Willem Scholten., et al. A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization . Vaccine . 1997; 15(10) , 1110-1113
60. Norihisa Goto , Jun-ichi Maeyama , Yoko Yasuda ., et al . Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant . Vaccine . 2000; 18(20)
61. 2164-2171 ),(Sveinbij?rn Gizurarson , Shin-ichi Tamura , Chikara Aizawa ., et al. Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit . Vaccine . 1992; 10(2), 101-106
62. Kunio Tochikubo , Masanori Isaka ,Yoko Yasuda ., et al. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin . Vaccine . 1998 ; 16(2-3),150-155
63. Svcinbj?rn Gizurarson , Shin-ichi Tamura , Takeshi Kurata ., et al . The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane . Vaccine . 1991; 9(11) , 825-832
64. Hideki Asanuma , Fusaoki koide , Yujiro Suzuki., et al. Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration. Vaccine . 1995; 13(1), 3-5
65. Hiroki Odagiri , Juehu Wang and Michael S.German . Function of the Human Insulin Promoter in Primary Cultured Islet Cells . The American Society for Biochemistry and Molecular Biology, Inc. Volume 271, Number 4, Issue of January 26, 1996 pp. 1909-1915
66. Shin-ichi Tamura , Kanemi Ishihara ,Kenji Miyata ., et al . Mechanism of enhancement of the immune responses to influenza vaccine with cholera toxin B subunit and a trace amount of holotoxin . Vaccine . 1995; 13(4), 339-341
67. Shin-ichi Tamura , Hirono Funato , Takashi Nagamine ., et al . Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB . Vaccine . 1989; 7(6), 503-505
68. Masanori Isaka , Takako Komiya , Motohide Takahashi ., et al. Recombinant cholera toxin Bsubunit (rCTB)as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus(DPT) combination vaccine. Vaccine. 2004;22(23-24)
69. P.G.Jenkins , A.B.Wrathmell, J.E.Harris .,et al. The effects of different adjuvants on intestinal antigen absorption and subsequent immune responses of the tilapian Oreochromis mossambicus . Fish & Shellfish Immunology . 1994; 4(3), 167-177
70. Jia-Bin Sun , Bin-Ling Li , Cecil Czerkinsky ., et al . Enhanced Immunological Tolerance against Allograft Rejection by Oral Administration of Allogeneic Antigen Linked to Cholera Toxin B Subunit . Clinical Immunology . 2000; 97(2) , 130-139
71. Jeffrey R.Powell and Etsuko W.Moriyama. Evolution of codon usage bias in Drosophila. Proc.Natl.Acad.Sci.USA. 1997.94:7784-7790
72. Lipscombe, M., C haries, I.G., Roberts, M., Dougan, G., Tite, J., and Fairweather, N.F. 1991. Intranasal immunization using the Bsubunit of the Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertussis P.69 antigen. Mol. Microbiol. 5:1385-1392
73. Purvis, I.J., Bettany, A.J., Santiago, T.C., Coggins, J.R., Duncan, K., Eason, R. et al. 1987. The efficiency of folding of some proteins is increased by controlled rates of translation in vivo. A hypothesis. J. Mol. Biol. 193:413-417
74. Haq, T.A., Mason, H.S., Clements, J.D., and Arntzen, C.J. 1995. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 268:714-716
75. Arakawa, T., Chaon, D.K.X., and Langridge, W.H.R. 1997. Expression of cholera toxin B subunit oligomers in transgenic potato plants. Transgenic Res. 6:403-413
76. Von Heijne, G. 1985. Signal sequences. J. Mol. Biol. 184:99-105
77. Munro, S. and Pelham, H.R.B. 1987. A C-terminal signal prevents secretion of luminal ER Proteins. Cell 48:899-907
78. Quinn D,Orci L,Ravazzola M,et al.intracellular transport and sorting of mutant human proinsulin that fail to form hexamers [J]cell Biol,1991,113(5):967-996
79. Arg-X-Lys/Arg-Arg[Van de Ven WJ.Roebroek AJ,Van Duijnhoven HL. Structure and function of enkaryotic proprotein. Processing enzymes of the subtilism family of serine proteases [J].crit Rev Oncog,1993,4(2):115-136
80. Gros 等[ Gros L,Montoliu L,Riu E,et al. Regulation production of mature insulin by non-βcells [J]. Hum Gene Ther.1997, 8:224922259
81. Falqui L,Martinenghi S,Severini GM,et al. Reversal of diabetes in mice by implantation of human fibroblasts genetically engineered to release mature human insulin [J]. Hum Gene Ther.1999, 10: 175321762
82. Norihisa Goto , Jun-ichi Maeyama, Yoko Yasuda and et al. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as as a mucosal adjuvant . (2000) . Vaccine . Volume 18 , Issue 20 , Pages 2164-2171.
83. Chilton MD,et al.Cell, 1977, 11:263-271
84. 兰丽珍,邓华超,孙辽.人胰岛素原基因突变体的构建.[J]第三军医大学学报.2004,24(19):1714-1716
85. Ooms G, et al. Gene, 14: 33-50
86. 陈燕,李金照,夏令朝等。人胰岛素原基因在大肠杆菌中高效外分泌表达。生物化学杂志,1995,11(6):637-641
87. 申同健,张继仁,于耀德等。人胰岛素原基因在酵母中的分泌表达。生物化学杂志,1987,3(2):153-158。
88. 李华,刘维权,刘海鹏等。人胰岛素基因重组杆状病毒在家蝇中表达的研究。中国医科大学学报,2004,33(2):113
89. D.Bucchini ,M.-A. Ripoche ,M.-G. Stinnakre and et al. Pancreatic expression of human insulin gene in transgenic mice . Developmental Biology .(1986) . Vol.83, pp.2511 -2515.
90. Zhang, J.,Davidson, L., Eisenbarth, GL, and Weiner, H.L. 1991. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Scl. USA 88:10252-10256.
91. Trentham, D.E.M Dynesius-Trentham, R.A.,Orav, E.J.M Combitchl, D.M Lorenzo, C., Sewell, K.L. et al. 1993. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261:1727-1730.
92. Weiner, H.L.M Mackin,G.A.M Matsul, M., Orav, E.J., Dawson, D.M. et al. 1993. Double-bling pilot trial of oral tolerization with myelin antigens in multiole sclerosis. Science 259:1321-1324.
93. Weiner, H.L., Friedman, A., Miller, A., Khoury, S.J., Al-Sabagh, A., Santos, L. et al. 1994. Oral tolerance:Immunologic mechanisms and treatment of animal and human organ-specific antoimmune diseases by oral administration of autoantigens . Annu. Rev. Immunol. 12:809-817.
94. Hancock, W.W.M Polanski, M., Zhang, J., Blogg, N., andWeiner, H.L. 1995. Suppression of insulitis in non-obese diabetic(NOD) mice by oral insulin administration is associated with selective expression of interlirkin-4 and -10, transforming growth factor-β, and prostaglandin-E. Am. J. Pathol. 147:1193-1199.
95. Zhang, J.,Davidson, L., Eisenbarth, GL, and Weiner, H.L. 1991. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Scl. USA 88:10252-10256.
96. Sun, J.-B., Rask, Czerkinsky, C.1994. Cholera toxin Bsubunit:an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. USA 91:10759-10799.
97. Sun, J.-B., Radk, C., Olsson , T., Holmgren, J., and Czerkinsky, C. 1996. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl. Acad. Sci. USA 93:7196-7201.
98. Bergerot, I., Ploix, C., Petersen,J., Moulin, V., Rask, C., Fabien, N. et al. 1997. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc. Natl. Acad. Sci. USA 94:4610-4614.
99. Weiner, H.L. 1994. Oral tolerance. Proc. Natl. Acad. Sci. USA 91:10762-10765.
100.Jhang JJ , et al . Vitro, 1974, 9: 253)
101. Jacek Osek, Michael Lebens and Jan Holmgren . (1995) . Improved medium for large-scale production of recombinant cholera toxin B subunit for vaccine purposes . Journal of Microbiological Methods . Volume 24 , Issue 2, Pages 117-123 .
102. J. Sanchez , S. Johansson, B. and et al . (1990) . Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination . Research in Microbiology . Volume 141,Issues 7-8 , Pages 971-979.
103 . Tae-Geum Kim, Andreas Gruber and William H. R. Langridge .(2004) . HIV-1 gp120 V3 cholera toxin B subunit fusion gene expression in transgenic potato . Protein Expression and Purification . Volume 37,Issue 1, Pages 196-202.
104. Zhaohui Gong, Yongfeng Jin, and Yaozhou Zhang . (2005). Oral administration of a cholera toxin B subunit –insulin fusion protein produced in silkworm protects against autoimmune diabetes . Journal of Biotechnology . Volume 119, Issue 1 , Pages 93-105.
105.Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA, 1994, 91:10759-10799.
106. Weiner HL. Oral tolerance. Proc Vatl Acad Sci USA, 1994, 91:10762-10765.
107. Sun JB, Radk C, Olsson T et al. Treatment of experimentalautoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin Bsubunit. Proc Natl Acad ScinUSA, 1996, 93:7196-7201.
108. Bergerot I , Ploix C, Petersen J et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA, 1997, 94:4610-4614.
109. Arakawa T , Chong DK , Merritt JL et al . Expression of cholera toxin Bsubunit oligomers in transgenic potato plants. Transgenic Res, 1997 , 6:403-413.
110,Mariko M,Isao M,Kozo T,et al.Novel oral microspheres of insulin wi th protease inhibitor protecting form enzymatic degradation.Int J Pharm,1992,78 ∶1～7
111,Isao M,Mariko M,Kozo T,et al.Hypoglycemic effect of novel oral mic rospheres of insulin with protease inhibitor in normal and diabetic rats.Int J P harm,1992,78∶9～16
112,George C,Chingyao Ch.Improvement of systemic absorption of insulin through eyes with absorption enhances.J Pharm Sci, 1989,78(10)∶815～818
113,Akira Y,Shinji U,Shozo M.Absorption enhancement of intrapul-1,monary administered insulin by various absorption enhanc ers and protease inhibitors in rats.J Pharm Pharmacol,1994,46∶14～18
114,Zhou XH,Li A,Wan Po.Peptide and protein drugs:II Non-parenteral route s of delivery.Int J Pharm,1991,75∶117～178
115.Machel C,Aprahamian M, Defontaine L, et al. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J Pharmacol, 1991,43:1
116.段明显,乐志操,马红等 中国药学杂志 1999,34(1):23
117.修志龙,齐冬健,苏志国 中国生化药物杂志,1996,17(4):172
118.孔艳 医药导报,1997,16(3):128
119.Saffran M, Pansky B, Thomas W, et al. Intranasal and the gastrointestiualtract. J Controlled Release,1997,46:89
120. Zive,Kidron M, Raz I, et al. J Pharm Sci,1994,83(6):792
121.Lipscombe M, Charles, IG, Roberts M et al . Intranasal immunization using the B subunit of the Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertussis P. 69 antigen. Mol Microbiol , 1991 ; 5: 1385-1392
122. Clements JD . Construction of a nontoxic fusion peptide for immunization against Escherichia strains that produce heat-labile and heat-stable enterotoxins . Infect Immun , 1990 , 58(5): 1159-1166
123. Polanski M , Melican NS , Zhang J et al . Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines . J Autoimmun , 1997 , 10: 339-346
124 . Ramiya VK , Maclaren NK . Insulin in diabetes prevention . Horm Res , 1997; 48 Suppl 4:67-70
125 . Von Herrath MC . Bystander suppression induced by oral tolerance . Res Immunol , 1997 , 148: 541-554
126 . Ramiya VK , Lan MS , Wasserfall CH et al . Immunization therapies in the prevention of diabetes . J Autoimmun , 1997 , 10:287-292
127 . Chaillous L , Lefevre H , Thivolet C et al . Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes : a multicentre randomised controlled trial . Diabete Insuline Orale group . Lancet, 2000, 356:545-549
128 . Pozzilli P , Pitocco D , Visalli N et al . No effect of oral insulin on residual beta-cell function in recent-onset type 1 diabetes {the IMDIAB VII} . IMDIAB Group . Diabetologia , 2000 , 43: 1000-1004
129 . Pozzilli P, Gisella Cavallo M. Oral insulin and the induction of tolerance in man: reality or fantasy ? Diabetes Metab Res Rev , 2000 ,16:306-307
130 . Chatenoud L . Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity : its relevance for treatment in established diabetes and islet transplantation . Diabetologia , 2001 , 44:521-536
131 . Arakawa T , Yu J , Chong DK et al . A plant-based choleraq toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes . Nat Biotechnol , 1998 , 16:934-938
2. Brandy Panunti, Ali . Jawa and Vivian A. Fonseca . Mechanisms and therapeutic targets in type 2 diabetes mellitus .Drug Discovery Today: Disease Mechanisms , Volume 1, Issue 2, November 2004, Pages 151-157
3. Cécile Dantzer, JoelSwendsen, Sylvie Maurice-Tison and ect . Anxiety and depression in juvenile diabetes : A critical review . Clinical Psychology Review , Volume 23,Issue 6, November 2003, Pages 787-800)
4. (Shaila Rodrigues, Elizabeth J Robinson, Heberto Ghezzo and ect . Interaction of body weight and ethnicity on risk of gestational diabetes mellitus . American Journal of Clinical Nutrition, Vol . 70, No. 6, 1083-1089, December 1999 )
5. Kathryn E. Wellen and G?khan S. Hotamisligil . Inflammation, stress, and diabetes . J. Clin. Invest. 115:1111-1119(2005))
6. D Kelleher and S Islam .The problem of integration: Asian people and diabetes . Journal of the Royal Society of Medicine , Vol 87 , Issue 7 414-417
7. Jaakko Tuomilehto, Gang Hu and Siamak Bidel . Coffee Consumption and Risk of Type 2 Diabetes Mellitus Among Middle-aged Finnish Men and Women . JAMA. 2004; 291:1213-1219.
8. Harold Lebovitz . Diabetes: Assessing the pipeline . Atherosclerosis Supplements , Volume 7,Issue 1, April 2006, Pages 43-49
9. Larissa Avilés-Santa,Karin Salinas, Beverley Adams-Huet and ect . Anthropometric features and cardiovascular risk in young LatinAmericans with type 2 diabetes mellitus . Jounrnal of Diabetes and its Complications . Volume 20, Issue 2, March-april 2006, Pages 69-74
10. Jennifer B.Marks and Philip Raskin . Cardiovascular risk in diabetes A brief review . Journal of Diabetes and its Complications , Volume
14,Issue 2, March-April 2000,Pages 108-115
11. Hashem B. EI-Serag, Howard Hampel and Fariba Javadi. The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic Evidence . Clinical Gastroenterology and Hepatology , Volume 4,Issue 3, March 2006, Pages 369-380
12. Francesco Chiarelli, Knut Dahl-J?rgensen , and Wieland Kiess. Diabetes in Childhood and Adolescence . Pediatric and Adolescent Medicine . Vol. 10
13. Brenda Leese . The costs of diabetes and its complications . Social Science & Medicine , Volume 35,Issue 10, November 1990, Pages 1303-1310
14. John A. Galloway . Current trends in diabetes therapy . Trends in Pharmacological Sciences , Volume 5, 1984, Pages 33-35
15. Dr.Linda Rae Zeitzoff MS, RN, CPNP, CDE. A Comprehensive Teview of Insulin Pump Therapy for the Nurse Practitioner . The Journal for Nurse Practitioners , Volume 1, Issue 4, November-December 2005, Pages 201-206
16. JW Anderson and AO Akan ji. Dietary fiber—an overview . Diabetes Care, Vol 14, Issue 12 1126-1131
17. MD FACP, FACELawrence Blonde, Director . Current challenges in diabetes management . Clinical Cornerstone , Volume 7, supplement 3, 2005, Pages S6-S17 Realizing Near-Normoglycemia
18. A Sharma and R Stein . Glucose-induced transcription of the insulin gene is mediated by factors required for beta-cell-type-specific expression . Mol Cell Biol . 1994 February; 14(2):871-879
19. M S German and J Wang . The insulin gene contains multiple transcriptional elements that respond to glucose . Mol Cell Biol. 1994 June; 14(6):4067-4075)
20. D J Drucker, J Philippe ,S Mojsov and ect . Glucagon-like peptide I Stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line . Proc Natl Acad Sci USA. 1987 May; 84(10): 3434-3438
21. Anders Lindholm MD, PhD, Associate Professor . New insulins in the treatment of diabetes mellitus . Best Practice & Research Clinical Gastroenterology , Volume 16, Issue 3, June 2002, Pages 475-492
22. P.Calceti , S.Salmaso and G.Walker ., et al . Development and in vivo evaluation of an oral insulin-PEG delivery system . European Journal of Pharmaceutical Sciences . 2004; 22(4), Pages 315-323
23. S.Sajeesh and Chandra P.Sharma . Ctclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticlesfor oral insulin delivery . International Journal of Pharmaceutics . online 18 June 2006
24. Mariko Morishita , Takahiro Goto and Koji Nakamura ., et al . Novel oral insulin delivery systems based on complexation polymer hydrogels: Single and multiple administration studies in type 1 and 2 diabetic rats . Journal of Controlled Release . 2006; 110(3), Pages 587-594
25. Eiichi Toorisaka, Masakazu Hashida and Noriho Kamiya ., et al . An enteric-coated dry emulsion formulation for oral insulin delivery . Journal of Controlled Release . 2005; 107(1) , Pages 91-96
26. Na Zhang , Qi N. Peng and H.Huang ., et al . Investigation of lectin-modified insulin liposomes as carriers for oral administration . International Journal of Pharmaceutics . 2005; 294(1-2) , Pages 247-259
27. Hou Zhenqing , Zhang Zhenxi and Zhang Chuanxin ., et al . Use of natural plant exudates (Sanguis Draxonis ) for sustained oral insulin delivery with dramatic reduction of glycemic effects in diabetic rats . Journal of Controlled Release . 2004; 97(3) , Pages 467-475
28. T.Morc?l , P.Nagappan and L.Nerenbaum ., et al . Calcium phosphate-PEG-insulin-casein(CAPIC) particles as oral deliverysystems for insulin . International Journal of Pharmaceutics . 2004; 277(1-2), Pages 91-97
29. Kiefer D, Pantuso T.Am Fam Physician, 2003, 68(8): 1539-1542
30. Li Liyan , Lu Xinguo .The Latest Study Progression of Panaxoside . Journal of Sichuan Continuing Education College of Medical Sciences . 2004;23(4)
31. Wang Yan and Ma Wenqiang . Research advance of the biological functions of ginsenoside . Feed industry. 2006 ; 27(6)
32. Xin Ying , Ni Jinsong , Jiang Xin ., et al. Inhibitory effect of
20(s)-ginsenoside Rg3 on tumor growth . Journal of Jilin University (medicine edition). 2006; 32(1)
33. Zhou Liang , Li Xianghua ,Pi Yihua ., et al. Effects of ginsenoside Rg1 on carbohydrate metabolism during exercise in rats . CHINESE JOURNAL OF CLINICAL REHABILITATION . 2005; 39(9)
34. Wang Ying , Cai Donglian . Advances of Research on Anti - Fatigue Effects of Panax ginseng . AMINO ACIDS AND BIOTIC RESOURCES . 2005; 27(3)
35. Feng Yinglu . Ginsenoside and tumor . FOREIGN MEDICAL SCIENCES (ONCOLOGYR SECTION) . 2005;32(9)
36. Zhang Aimin . Effect of the Ginseng(P. schin-seng Nees.)on the Endurance Capacity of Mice . JOURNAL OF LIAOCHENG TEACHERS UNIVERSITY (NATURAL SCIENCE EDITION) . 2001; 14(3)
37. Zhang Nianzhi , Han Mingxiang ,Zhou Yixuan . Clinical Study on Ginseng Injection for Patients with Deficiency of Heart-Qi Syndrome of Angina . JOURNAL OF EMERGENCY SYNDROMES IN CHINESE MEDICINE . 2000 ; 9(4)
38. Li Liyan , Lu Xinguo . Effect of ginsenoside on cardiovascular and neurological systems and its role against exercise-induced fatigue . CHINESE JOURNAL OF CLINICAL REHABILITATION . 2005; 16(9)
39. Wang Jiyan , Shun Guangzhi , Li Xianggao . A Review of the Studies on Chemical Constituents and Pharmaceutical Activities of the Fruitof Panax ginseng . JOURNAL OF JILIN AGRICULTURAL UNIVERSIT .2005; 27(1)
40. Wang Weixia , Wang Wei ,Chen Keji . Protective Effect and Mechanism of Ginsenosides on Central Nerve System of Animals . CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE . 2005;25(1)
41. Wan Xuying , Zhang Yani , Zhang Chen . Experimental Study on Anti-hepatocarcinoma Effect of Maorenshen injection in vitro . JOURNAL OF ZHEJIANG COLLEGE OF TRADITIONAL CHINESE MEDICINE .2004;28(2)
42. Fu Xiaoqing , Cai Zhongwei, Yang Xianrong. General Situation Study of Ginseng delaying senile process of central nervous system(CNS) . CHINESE ARCHIVES OF TRADITIONAL CHINESE MEDICINE .2003;21(7)
43. Wu Chenglin , Gao Pingyang. Study on Ginseng Increasing Mouse Ability of Sports and Fatigue Strength . SICHUAN SPORTS SCIENCE. 2003;1
44. Dan Hanxiong, Liu Chuixia , Jiang Nan. Immunoenhancement Effects of Panaxadiol Saponins Isolated from Panax Notoginseng on Experimental Animal. JOURNAL OF HUBEI COLLEGE TRADITIONAL CHINESE MEDICINE . 2003;5(1)
45. 任杰红,陈林芳,张路晗等。人参皂苷 Rg1 的免疫促进作用。中药新药与临床药理 。2002;13(2)
46. Yu Lijun,Dou Deqiang,Chen Xiaohong., et al. Ginsenoside-Ro enhances cell proliferation and modulates Th1/Th2 cytokines production in murine splenocytes . ACTA PHARMACEUTICA SINICA .2005; 40(4)
47. Jongsung Lee, Eunsun Jung, Jiyoung Lee., et al . Panax ginseng induces human Type I collagen synthesis through activation of Smad signaling . Journal of Ethnopharmacology . 2006; Avalable online 3 July
48. Zhijun Song , Claus Moser, Hong Wu ., et al . Cytokine modulating effect of ginseng treatment in a mouse model of Pseudomonasaeruginosa lung infection . Journal of Cystic Fibrosis .2003; 2,( 3), Pages 112-119
49. Chi Dakui , Yu Xiaofeng, Qu Shaochun., et al. Effect of 20S-protopanaxadiol saponins on blood lipid metabolism and antioxidative activity in hyperlipidemia rats . CHINESE TRADITIONAL AND HERBAL DRUGS . 2004;35(4)
50. Xu Chengshui , Zhang Xiangpei. The influence of red ginseng (P. schin-seng Nees . ) on blood sugar in rat. JOURNAL OF TAISHAN UNIVERSITY.2003;25(3)
51. Wang Benxiang,Zhou Qiuli,Yang Ming ., et al. Hypoglycemic mechanism of ginseng glycopeptide . ACTA PHARMACOLOGICA SINICA. 2003;24(1)
52. Chen Guanmin, Chen Xiaoping, He Ling ., et al . An Experimental Study on Function of Ginseng in Lipid Level and Anti-aging . PRACTICAL PREVENTIVE MEDICINE. 2002;9(4)
53. Luo Lan , Yin Huijun, Zhang Ying., et al. Effect of ginseng fruit saponins on insulin sensitivity index in high fat-fed rats. JOURNAL OF CHINESE INTEGRATIVE MEDICINE. 2005;6(3)
54. Zhang Xinmu , Qu Shaochun, Chi Dakui ., et al. Effects of ginsenoside-Rb on blood lipid metabolism and anti-oxidation in hyperlipidemia rats. CHINA JOURNAL OF CHINESE MATERIA MEDICA. 2004;29(11)
55. Hideyuki Kajiwara , Andrew M.Hemmings and Hisashi Hirano . Evidence of metal binding activities of pentadecapeptide from Panax ginseng . Journal of Chromatography B: Biomedical Sciences and Applications . 1996; 687( 2 ), Pages 443-448
56. ChunXiang Qiao , Ryousuke Den and Koutaro Kudo ., et al . Ginseng enhances contextual fear conditioning and neurogenesis in rats. Neuroscience Research . 2005; 51(1) , Pages 31-38
57. Jacek Osek ,Michael Lebens and Jan Holmgren . Improved medium for large-scale production of recombinant cholera toxin B subunit for vaccine purposes . Journal of Microbiological Methods . 1995; 24(2), Pages 117-123
58. J.Sanchez ,S.Johansson,B.L?wenadler ,et al . Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination. Research in Microbiology . 1990; 141(7-8) , Pages 971-979
59. Bernard de Geus , Maike Dol-Bosman , Jan Willem Scholten., et al. A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization . Vaccine . 1997; 15(10) , 1110-1113
60. Norihisa Goto , Jun-ichi Maeyama , Yoko Yasuda ., et al . Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant . Vaccine . 2000; 18(20)
61. 2164-2171 ),(Sveinbij?rn Gizurarson , Shin-ichi Tamura , Chikara Aizawa ., et al. Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit . Vaccine . 1992; 10(2), 101-106
62. Kunio Tochikubo , Masanori Isaka ,Yoko Yasuda ., et al. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin . Vaccine . 1998 ; 16(2-3),150-155
63. Svcinbj?rn Gizurarson , Shin-ichi Tamura , Takeshi Kurata ., et al . The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane . Vaccine . 1991; 9(11) , 825-832
64. Hideki Asanuma , Fusaoki koide , Yujiro Suzuki., et al. Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration. Vaccine . 1995; 13(1), 3-5
65. Hiroki Odagiri , Juehu Wang and Michael S.German . Function of the Human Insulin Promoter in Primary Cultured Islet Cells . The American Society for Biochemistry and Molecular Biology, Inc. Volume 271, Number 4, Issue of January 26, 1996 pp. 1909-1915
66. Shin-ichi Tamura , Kanemi Ishihara ,Kenji Miyata ., et al . Mechanism of enhancement of the immune responses to influenza vaccine with cholera toxin B subunit and a trace amount of holotoxin . Vaccine . 1995; 13(4), 339-341
67. Shin-ichi Tamura , Hirono Funato , Takashi Nagamine ., et al . Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB . Vaccine . 1989; 7(6), 503-505
68. Masanori Isaka , Takako Komiya , Motohide Takahashi ., et al. Recombinant cholera toxin Bsubunit (rCTB)as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus(DPT) combination vaccine. Vaccine. 2004;22(23-24)
69. P.G.Jenkins , A.B.Wrathmell, J.E.Harris .,et al. The effects of different adjuvants on intestinal antigen absorption and subsequent immune responses of the tilapian Oreochromis mossambicus . Fish & Shellfish Immunology . 1994; 4(3), 167-177
70. Jia-Bin Sun , Bin-Ling Li , Cecil Czerkinsky ., et al . Enhanced Immunological Tolerance against Allograft Rejection by Oral Administration of Allogeneic Antigen Linked to Cholera Toxin B Subunit . Clinical Immunology . 2000; 97(2) , 130-139
71. Jeffrey R.Powell and Etsuko W.Moriyama. Evolution of codon usage bias in Drosophila. Proc.Natl.Acad.Sci.USA. 1997.94:7784-7790
72. Lipscombe, M., C haries, I.G., Roberts, M., Dougan, G., Tite, J., and Fairweather, N.F. 1991. Intranasal immunization using the Bsubunit of the Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertussis P.69 antigen. Mol. Microbiol. 5:1385-1392
73. Purvis, I.J., Bettany, A.J., Santiago, T.C., Coggins, J.R., Duncan, K., Eason, R. et al. 1987. The efficiency of folding of some proteins is increased by controlled rates of translation in vivo. A hypothesis. J. Mol. Biol. 193:413-417
74. Haq, T.A., Mason, H.S., Clements, J.D., and Arntzen, C.J. 1995. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 268:714-716
75. Arakawa, T., Chaon, D.K.X., and Langridge, W.H.R. 1997. Expression of cholera toxin B subunit oligomers in transgenic potato plants. Transgenic Res. 6:403-413
76. Von Heijne, G. 1985. Signal sequences. J. Mol. Biol. 184:99-105
77. Munro, S. and Pelham, H.R.B. 1987. A C-terminal signal prevents secretion of luminal ER Proteins. Cell 48:899-907
78. Quinn D,Orci L,Ravazzola M,et al.intracellular transport and sorting of mutant human proinsulin that fail to form hexamers [J]cell Biol,1991,113(5):967-996
79. Arg-X-Lys/Arg-Arg[Van de Ven WJ.Roebroek AJ,Van Duijnhoven HL. Structure and function of enkaryotic proprotein. Processing enzymes of the subtilism family of serine proteases [J].crit Rev Oncog,1993,4(2):115-136
80. Gros 等[ Gros L,Montoliu L,Riu E,et al. Regulation production of mature insulin by non-βcells [J]. Hum Gene Ther.1997, 8:224922259
81. Falqui L,Martinenghi S,Severini GM,et al. Reversal of diabetes in mice by implantation of human fibroblasts genetically engineered to release mature human insulin [J]. Hum Gene Ther.1999, 10: 175321762
82. Norihisa Goto , Jun-ichi Maeyama, Yoko Yasuda and et al. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as as a mucosal adjuvant . (2000) . Vaccine . Volume 18 , Issue 20 , Pages 2164-2171.
83. Chilton MD,et al.Cell, 1977, 11:263-271
84. 兰丽珍,邓华超,孙辽.人胰岛素原基因突变体的构建.[J]第三军医大学学报.2004,24(19):1714-1716
85. Ooms G, et al. Gene, 14: 33-50
86. 陈燕,李金照,夏令朝等。人胰岛素原基因在大肠杆菌中高效外分泌表达。生物化学杂志,1995,11(6):637-641
87. 申同健,张继仁,于耀德等。人胰岛素原基因在酵母中的分泌表达。生物化学杂志,1987,3(2):153-158。
88. 李华,刘维权,刘海鹏等。人胰岛素基因重组杆状病毒在家蝇中表达的研究。中国医科大学学报,2004,33(2):113
89. D.Bucchini ,M.-A. Ripoche ,M.-G. Stinnakre and et al. Pancreatic expression of human insulin gene in transgenic mice . Developmental Biology .(1986) . Vol.83, pp.2511 -2515.
90. Zhang, J.,Davidson, L., Eisenbarth, GL, and Weiner, H.L. 1991. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Scl. USA 88:10252-10256.
91. Trentham, D.E.M Dynesius-Trentham, R.A.,Orav, E.J.M Combitchl, D.M Lorenzo, C., Sewell, K.L. et al. 1993. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261:1727-1730.
92. Weiner, H.L.M Mackin,G.A.M Matsul, M., Orav, E.J., Dawson, D.M. et al. 1993. Double-bling pilot trial of oral tolerization with myelin antigens in multiole sclerosis. Science 259:1321-1324.
93. Weiner, H.L., Friedman, A., Miller, A., Khoury, S.J., Al-Sabagh, A., Santos, L. et al. 1994. Oral tolerance:Immunologic mechanisms and treatment of animal and human organ-specific antoimmune diseases by oral administration of autoantigens . Annu. Rev. Immunol. 12:809-817.
94. Hancock, W.W.M Polanski, M., Zhang, J., Blogg, N., andWeiner, H.L. 1995. Suppression of insulitis in non-obese diabetic(NOD) mice by oral insulin administration is associated with selective expression of interlirkin-4 and -10, transforming growth factor-β, and prostaglandin-E. Am. J. Pathol. 147:1193-1199.
95. Zhang, J.,Davidson, L., Eisenbarth, GL, and Weiner, H.L. 1991. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Scl. USA 88:10252-10256.
96. Sun, J.-B., Rask, Czerkinsky, C.1994. Cholera toxin Bsubunit:an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. USA 91:10759-10799.
97. Sun, J.-B., Radk, C., Olsson , T., Holmgren, J., and Czerkinsky, C. 1996. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl. Acad. Sci. USA 93:7196-7201.
98. Bergerot, I., Ploix, C., Petersen,J., Moulin, V., Rask, C., Fabien, N. et al. 1997. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc. Natl. Acad. Sci. USA 94:4610-4614.
99. Weiner, H.L. 1994. Oral tolerance. Proc. Natl. Acad. Sci. USA 91:10762-10765.
100.Jhang JJ , et al . Vitro, 1974, 9: 253)
101. Jacek Osek, Michael Lebens and Jan Holmgren . (1995) . Improved medium for large-scale production of recombinant cholera toxin B subunit for vaccine purposes . Journal of Microbiological Methods . Volume 24 , Issue 2, Pages 117-123 .
102. J. Sanchez , S. Johansson, B. and et al . (1990) . Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination . Research in Microbiology . Volume 141,Issues 7-8 , Pages 971-979.
103 . Tae-Geum Kim, Andreas Gruber and William H. R. Langridge .(2004) . HIV-1 gp120 V3 cholera toxin B subunit fusion gene expression in transgenic potato . Protein Expression and Purification . Volume 37,Issue 1, Pages 196-202.
104. Zhaohui Gong, Yongfeng Jin, and Yaozhou Zhang . (2005). Oral administration of a cholera toxin B subunit –insulin fusion protein produced in silkworm protects against autoimmune diabetes . Journal of Biotechnology . Volume 119, Issue 1 , Pages 93-105.
105.Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA, 1994, 91:10759-10799.
106. Weiner HL. Oral tolerance. Proc Vatl Acad Sci USA, 1994, 91:10762-10765.
107. Sun JB, Radk C, Olsson T et al. Treatment of experimentalautoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin Bsubunit. Proc Natl Acad ScinUSA, 1996, 93:7196-7201.
108. Bergerot I , Ploix C, Petersen J et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA, 1997, 94:4610-4614.
109. Arakawa T , Chong DK , Merritt JL et al . Expression of cholera toxin Bsubunit oligomers in transgenic potato plants. Transgenic Res, 1997 , 6:403-413.
110,Mariko M,Isao M,Kozo T,et al.Novel oral microspheres of insulin wi th protease inhibitor protecting form enzymatic degradation.Int J Pharm,1992,78 ∶1～7
111,Isao M,Mariko M,Kozo T,et al.Hypoglycemic effect of novel oral mic rospheres of insulin with protease inhibitor in normal and diabetic rats.Int J P harm,1992,78∶9～16
112,George C,Chingyao Ch.Improvement of systemic absorption of insulin through eyes with absorption enhances.J Pharm Sci, 1989,78(10)∶815～818
113,Akira Y,Shinji U,Shozo M.Absorption enhancement of intrapul-1,monary administered insulin by various absorption enhanc ers and protease inhibitors in rats.J Pharm Pharmacol,1994,46∶14～18
114,Zhou XH,Li A,Wan Po.Peptide and protein drugs:II Non-parenteral route s of delivery.Int J Pharm,1991,75∶117～178
115.Machel C,Aprahamian M, Defontaine L, et al. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J Pharmacol, 1991,43:1
116.段明显,乐志操,马红等 中国药学杂志 1999,34(1):23
117.修志龙,齐冬健,苏志国 中国生化药物杂志,1996,17(4):172
118.孔艳 医药导报,1997,16(3):128
119.Saffran M, Pansky B, Thomas W, et al. Intranasal and the gastrointestiualtract. J Controlled Release,1997,46:89
120. Zive,Kidron M, Raz I, et al. J Pharm Sci,1994,83(6):792
121.Lipscombe M, Charles, IG, Roberts M et al . Intranasal immunization using the B subunit of the Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertussis P. 69 antigen. Mol Microbiol , 1991 ; 5: 1385-1392
122. Clements JD . Construction of a nontoxic fusion peptide for immunization against Escherichia strains that produce heat-labile and heat-stable enterotoxins . Infect Immun , 1990 , 58(5): 1159-1166
123. Polanski M , Melican NS , Zhang J et al . Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines . J Autoimmun , 1997 , 10: 339-346
124 . Ramiya VK , Maclaren NK . Insulin in diabetes prevention . Horm Res , 1997; 48 Suppl 4:67-70
125 . Von Herrath MC . Bystander suppression induced by oral tolerance . Res Immunol , 1997 , 148: 541-554
126 . Ramiya VK , Lan MS , Wasserfall CH et al . Immunization therapies in the prevention of diabetes . J Autoimmun , 1997 , 10:287-292
127 . Chaillous L , Lefevre H , Thivolet C et al . Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes : a multicentre randomised controlled trial . Diabete Insuline Orale group . Lancet, 2000, 356:545-549
128 . Pozzilli P , Pitocco D , Visalli N et al . No effect of oral insulin on residual beta-cell function in recent-onset type 1 diabetes {the IMDIAB VII} . IMDIAB Group . Diabetologia , 2000 , 43: 1000-1004
129 . Pozzilli P, Gisella Cavallo M. Oral insulin and the induction of tolerance in man: reality or fantasy ? Diabetes Metab Res Rev , 2000 ,16:306-307
130 . Chatenoud L . Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity : its relevance for treatment in established diabetes and islet transplantation . Diabetologia , 2001 , 44:521-536
131 . Arakawa T , Yu J , Chong DK et al . A plant-based choleraq toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes . Nat Biotechnol , 1998 , 16:934-938